Imaging DNA damage response by γH2AX <i>in vivo</i> predicts treatment response to Lutetium-177 radioligand therapy and suggests senescence as a therapeutically desirable outcome
Edward O’Neill, Michael Mosley, Bart Cornelissen
Abstract
Dual isotope SPECT imaging can provide individualized tumor dose-responses that can be used to predict lutetium-177 treatment efficacy. This bio-dosimeter metric appears to be dependent upon the extent of senescence induction and suggests an integral role that senescence plays in lutetium-177 treatment efficacy.
Topics & Concepts
In vivoEx vivoRadionuclide therapyDNA damageApoptosisSenescenceClonogenic assayCancer researchMedicineIn vitroProstate cancerNuclear medicineChemistryCancerBiologyInternal medicineDNABiotechnologyBiochemistryRadiopharmaceutical Chemistry and ApplicationsMedical Imaging Techniques and ApplicationsLung Cancer Research Studies